The pitfalls of biomarker‐based classification schemes
- 10 July 2017
- journal article
- letter
- Published by Wiley in Alzheimer's & Dementia
- Vol. 13 (9), 1072-1074
- https://doi.org/10.1016/j.jalz.2017.06.002
Abstract
No abstract availableFunding Information
- Generalitat de Catalunya (2014SGR‐0235, IF15/00060)
- Instituto de Salud Carlos III
This publication has 13 references indexed in Scilit:
- Synergistic interaction between amyloid and tau predicts the progression to dementiaAlzheimer's & Dementia, 2016
- Longitudinal brain structural changes in preclinical Alzheimer's diseaseAlzheimer's & Dementia, 2016
- A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkersNeurology, 2016
- CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysisThe Lancet Neurology, 2016
- Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findingsBrain, 2015
- Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stageBrain, 2015
- Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's diseaseBrain, 2014
- Cerebrospinal fluid β‐amyloid and phospho‐tau biomarker interactions affecting brain structure in preclinical Alzheimer diseaseAnnals of Neurology, 2014
- Amyloid‐β associated volume loss occurs only in the presence of phospho‐tauAnnals of Neurology, 2011
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009